NCT03952650: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03952650 |
|---|---|
| Title | Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falciparum Infection in Bancoumana and Surrounding Areas, Mali |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 23, 2019 |
| Completion date | Feb. 10, 2021 |
| Required reporting date | Feb. 10, 2022, midnight |
| Actual reporting date | Feb. 7, 2022 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |